An exploratory double‐blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with H untington's disease
Year: 2015
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: AIMS: Selisistat, a selective SirT1 inhibitor is being developed as a potentially disease-modifying therapeutic for Huntington's disease (HD). This was the first study of selisistat in HD patients and was primarily aimed at development of pharmacodynamic biomarkers. METHODS: This was a randomized, double-blind, placebo-controlled, multicentre exploratory study. Fifty-five male and female patients in early stage HD were randomized to receive 10 mg or 100 mg of selisistat or placebo once daily for 14 days. Blood sampling, clinical and safety assessments were conducted throughout the study. Candidate pharmacodynamic markers included circulating soluble huntingtin and innate immune markers. RESULTS: Selisistat was found to be safe and well tolerated, and systemic exposure parameters showed that the average steady-state plasma concentration achieved at the 10 mg dose level (125 nm) was comparable with the IC50 for SirT1 inhibition. No adverse effects on motor, cognitive or functional readouts were recorded. While circulating levels of soluble huntingtin were not affected by selisistat in this study, the biological samples collected have allowed development of assay technology for use in future studies. No effects on innate immune markers were seen. CONCLUSIONS: Selisistat was found to be safe and well tolerated in early stage HD patients at plasma concentrations within the anticipated therapeutic concentration range.
DOI: 10.1111/bcp.12512
Authors: Sigurd D. Süssmuth, Salman Haider, G. Bernhard Landwehrmeyer, Ruth Farmer, Chris Frost, Giovanna Tripepi, Claus A. Andersen, Marco Di Bacco, Claudia Lamanna, Enrica Diodato, Luisa Massai, Daniela Diamanti, Elisa Mori, Letizia Magnoni, Jens Dreyhaupt, Karin Schiefele, David Craufurd, Carsten Saft, Monika Rudzinska, Danuta Ryglewicz, Michael Orth, Sebastian Brzozy, Anna Baran, Giuseppe Pollio, Ralph Andre, Sarah J. Tabrizi, Borje Darpo, Goran Westerberg
Institutions: University Hospital Ulm, UCL Queen Square Institute of Neurology, University College London, London School of Hygiene & Tropical Medicine, Siena Biotech (Italy), European Huntington's Disease Network, Universität Ulm, Manchester Academic Health Science Centre, University of Manchester, St. Josef-Hospital, Ruhr University Bochum, Medical University of Silesia, Institute of Psychiatry and Neurology, Danderyds sjukhus, Karolinska Institutet
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: bronze
Funder: Medical Research Council
OpenAlex ID: W2131827606
